Faustino Margarida, Silva Sara, Costa Eduardo M, Pereira Ana Margarida, Pereira Joana Odila, Oliveira Ana Sofia, Ferreira Carlos M H, Pereira Carla F, Durão Joana, Pintado Manuela E, Carvalho Ana P
CBQF-Centro de Biotecnologia e Química Fina-Laboratório Associado, Universidade Católica Portuguesa, Escola Superior de Biotecnologia, Rua Diogo Botelho 1327, 4169-005 Porto, Portugal.
Amyris Bio Products Portugal, Unipessoal Lda, Rua Diogo Botelho, 1327, 4169-005 Porto, Portugal.
Pathogens. 2023 Jun 28;12(7):885. doi: 10.3390/pathogens12070885.
Urinary tract infections (UTIs) are a common public health problem, mainly caused by uropathogenic (UPEC). Patients with chronic UTIs are usually treated with long-acting prophylactic antibiotics, which promotes the development of antibiotic-resistant UPEC strains and may complicate their long-term management. D-mannose and extracts rich in D-mannose such as mannan oligosaccharides (MOS; D-mannose oligomers) are promising alternatives to antibiotic prophylaxis due to their ability to inhibit bacterial adhesion to urothelial cells and, therefore, infection. This highlights the therapeutic potential and commercial value of using them as health supplements. Studies on the effect of MOS in UTIs are, however, scarce. Aiming to evaluate the potential benefits of using MOS extracts in UTIs prophylaxis, their ability to inhibit the adhesion of UPEC to urothelial cells and its mechanism of action were assessed. Additionally, the expression levels of the pro-inflammatory marker interleukin 6 (IL-6) were also evaluated. After characterizing their cytotoxic profiles, the preliminary results indicated that MOS extracts have potential to be used for the handling of UTIs and demonstrated that the mechanism through which they inhibit bacterial adhesion is through the competitive inhibition of FimH adhesins through the action of mannose, validated by a bacterial growth impact assessment.
尿路感染（UTIs）是一个常见的公共卫生问题，主要由尿路致病性大肠杆菌（UPEC）引起。慢性尿路感染患者通常采用长效预防性抗生素治疗，这促进了抗生素耐药性UPEC菌株的产生，并可能使他们的长期治疗复杂化。D-甘露糖和富含D-甘露糖的提取物，如甘露寡糖（MOS；D-甘露糖低聚物），由于它们能够抑制细菌与尿道上皮细胞的粘附，从而抑制感染，因此是抗生素预防的有前景的替代物。这凸显了将它们用作健康补充剂的治疗潜力和商业价值。然而，关于MOS在尿路感染中的作用的研究很少。为了评估使用MOS提取物预防尿路感染的潜在益处，评估了它们抑制UPEC与尿道上皮细胞粘附的能力及其作用机制。此外，还评估了促炎标志物白细胞介素6（IL-6）的表达水平。在表征了它们的细胞毒性特征后，初步结果表明MOS提取物有潜力用于处理尿路感染，并证明它们抑制细菌粘附的机制是通过甘露糖的作用竞争性抑制FimH粘附素，这一点通过细菌生长影响评估得到了验证。
